Coronaviruses

Coronaviruses

Arbutus Biopharma Announces Multiple Abstracts Accepted for Oral and Poster Presentations at EASL 2021 International Liver Congress

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on developing a cure for chronic hepatitis B virus (HBV) infection, has announced that five abstracts have been accepted for presentation at the upcoming International Liver Congress (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL)